Skip to main content
Top
Published in: Clinical Research in Cardiology 2/2018

01-08-2018 | Review

Progress in heart failure treatment in Germany

Authors: Mark Luedde, Martina E. Spehlmann, Norbert Frey

Published in: Clinical Research in Cardiology | Special Issue 2/2018

Login to get access

Abstract

Acute and chronic heart failure is still a major cause of morbidity and mortality in Europe. Nevertheless, significant progress has been made in diagnosis and treatment of heart failure as well as in unraveling its molecular causes. Here, we focus on some relevant contributions to these achievements by German cardiovascular clinicians and scientists.
Literature
1.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGFC, Coats AJS, Falk V, González-Juanatey JR (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2220CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGFC, Coats AJS, Falk V, González-Juanatey JR (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2220CrossRefPubMed
2.
go back to reference Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94:11514–11519CrossRefPubMed Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94:11514–11519CrossRefPubMed
7.
go back to reference Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC (2007) Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 53:284–291. https://doi.org/10.1373/clinchem.2006.076828 CrossRefPubMed Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC (2007) Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 53:284–291. https://​doi.​org/​10.​1373/​clinchem.​2006.​076828 CrossRefPubMed
8.
go back to reference Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17:581–588. https://doi.org/10.1038/nm.2354 CrossRefPubMed Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17:581–588. https://​doi.​org/​10.​1038/​nm.​2354 CrossRefPubMed
11.
go back to reference Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM (2015) Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17:214–223. https://doi.org/10.1002/ejhf.203 CrossRefPubMed Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM (2015) Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail 17:214–223. https://​doi.​org/​10.​1002/​ejhf.​203 CrossRefPubMed
12.
go back to reference Giannitsis E, Muller-Bardorff M, Lehrke S, Wiegand U, Tolg R, Weidtmann B, Hartmann F, Richardt G, Katus HA (2001) Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 104:630–635CrossRefPubMed Giannitsis E, Muller-Bardorff M, Lehrke S, Wiegand U, Tolg R, Weidtmann B, Hartmann F, Richardt G, Katus HA (2001) Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 104:630–635CrossRefPubMed
16.
go back to reference Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Muller S, Kayvanpour E, Vogel B, Sedaghat-Hamedani F, Lim WK, Zhao X, Fradkin D, Kohler D, Fischer S, Franke J, Marquart S, Barb I, Li DT, Amr A, Ehlermann P, Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, Isnard R, Komajda M, Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, Eiskjaer H, Jorgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG, Deprez RH, Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A, Bolognesi M, Bellazzi R, Morner S, Bermejo JL, Monserrat L, Villard E, Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, Katus HA, Meder B (2015) Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 36:1123–1135. https://doi.org/10.1093/eurheartj/ehu301 aCrossRefPubMed Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Muller S, Kayvanpour E, Vogel B, Sedaghat-Hamedani F, Lim WK, Zhao X, Fradkin D, Kohler D, Fischer S, Franke J, Marquart S, Barb I, Li DT, Amr A, Ehlermann P, Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, Isnard R, Komajda M, Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, Eiskjaer H, Jorgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG, Deprez RH, Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A, Bolognesi M, Bellazzi R, Morner S, Bermejo JL, Monserrat L, Villard E, Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, Katus HA, Meder B (2015) Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 36:1123–1135. https://​doi.​org/​10.​1093/​eurheartj/​ehu301 aCrossRefPubMed
17.
go back to reference Meder B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Frese K, Lai A, Nietsch R, Scheiner C, Mester S, Bordalo DM, Amr A, Dietrich C, Pils D, Siede D, Hund H, Bauer A, Holzer DB, Ruhparwar A, Mueller-Hennessen M, Weichenhan D, Plass C, Weis T, Backs J, Wuerstle M, Keller A, Katus HA, Posch AE (2017) Epigenome-Wide Association Study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. Circulation 136:1528–1544. https://doi.org/10.1161/CIRCULATIONAHA.117.027355 CrossRefPubMed Meder B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Frese K, Lai A, Nietsch R, Scheiner C, Mester S, Bordalo DM, Amr A, Dietrich C, Pils D, Siede D, Hund H, Bauer A, Holzer DB, Ruhparwar A, Mueller-Hennessen M, Weichenhan D, Plass C, Weis T, Backs J, Wuerstle M, Keller A, Katus HA, Posch AE (2017) Epigenome-Wide Association Study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. Circulation 136:1528–1544. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​117.​027355 CrossRefPubMed
21.
go back to reference Bavendiek U, Aguirre Davila L, Schwab SA, Phillip SA, Westenfeld R, Maier LS, Stoerk S, Weber K, Koch A, Bauersachs J, Group D-Hs (2017) P6168 Digitoxin serum concentrations affecting patient safety and potential outcome in patients with HFrEF-analyses of the ongoing DIGIT-HF-trial. Eur Heart J 38(suppl_1):P6168CrossRef Bavendiek U, Aguirre Davila L, Schwab SA, Phillip SA, Westenfeld R, Maier LS, Stoerk S, Weber K, Koch A, Bauersachs J, Group D-Hs (2017) P6168 Digitoxin serum concentrations affecting patient safety and potential outcome in patients with HFrEF-analyses of the ongoing DIGIT-HF-trial. Eur Heart J 38(suppl_1):P6168CrossRef
23.
go back to reference Ahmed A, Aronow WS, Fleg JL (2006) Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. Am J Ther 13:325–331CrossRefPubMedPubMedCentral Ahmed A, Aronow WS, Fleg JL (2006) Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. Am J Ther 13:325–331CrossRefPubMedPubMedCentral
24.
go back to reference Tschope C, Birner C, Bohm M, Bruder O, Frantz S, Luchner A, Maier L, Stork S, Kherad B, Laufs U (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin Res Cardiol 107:1–19. https://doi.org/10.1007/s00392-017-1170-6 CrossRefPubMed Tschope C, Birner C, Bohm M, Bruder O, Frantz S, Luchner A, Maier L, Stork S, Kherad B, Laufs U (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin Res Cardiol 107:1–19. https://​doi.​org/​10.​1007/​s00392-017-1170-6 CrossRefPubMed
26.
go back to reference Bohm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, McKelvie RS, Anand IS, Massie BM, Carson PE, McMurray JJ, Committees IP, Investigators (2014) Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail 16:778–787. https://doi.org/10.1002/ejhf.85 CrossRefPubMed Bohm M, Perez AC, Jhund PS, Reil JC, Komajda M, Zile MR, McKelvie RS, Anand IS, Massie BM, Carson PE, McMurray JJ, Committees IP, Investigators (2014) Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail 16:778–787. https://​doi.​org/​10.​1002/​ejhf.​85 CrossRefPubMed
27.
go back to reference van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, Investigators S (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53:2150–2158. https://doi.org/10.1016/j.jacc.2009.02.046 CrossRefPubMed van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, Investigators S (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53:2150–2158. https://​doi.​org/​10.​1016/​j.​jacc.​2009.​02.​046 CrossRefPubMed
30.
go back to reference Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo DHFI (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791. https://doi.org/10.1001/jama.2013.905 CrossRefPubMed Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo DHFI (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791. https://​doi.​org/​10.​1001/​jama.​2013.​905 CrossRefPubMed
31.
go back to reference Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators T (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392. https://doi.org/10.1056/NEJMoa1313731 CrossRefPubMed Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators T (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383–1392. https://​doi.​org/​10.​1056/​NEJMoa1313731 CrossRefPubMed
32.
go back to reference Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen HD, Duvinage A, Hoischen N, von Oehsen K, Schwarz S, Hasenfuss G, Halle M, Pieske B, Edelmann F (2015) Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol 22:582–593. https://doi.org/10.1177/2047487314526071 CrossRefPubMed Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen HD, Duvinage A, Hoischen N, von Oehsen K, Schwarz S, Hasenfuss G, Halle M, Pieske B, Edelmann F (2015) Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol 22:582–593. https://​doi.​org/​10.​1177/​2047487314526071​ CrossRefPubMed
33.
go back to reference Hasenfuss G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der Heyden J, Lang I, Petrie MC, Cleland JG, Leon M, Kaye DM, Investigators RL-Hs (2016) A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet 387:1298–1304. https://doi.org/10.1016/S0140-6736(16)00704-2 CrossRefPubMed Hasenfuss G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der Heyden J, Lang I, Petrie MC, Cleland JG, Leon M, Kaye DM, Investigators RL-Hs (2016) A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet 387:1298–1304. https://​doi.​org/​10.​1016/​S0140-6736(16)00704-2 CrossRefPubMed
34.
go back to reference Sondergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, Franzen O, Neuzil P, Ihlemann N, Gustafsson F (2014) Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 16:796–801. https://doi.org/10.1002/ejhf.111 CrossRefPubMed Sondergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, Franzen O, Neuzil P, Ihlemann N, Gustafsson F (2014) Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 16:796–801. https://​doi.​org/​10.​1002/​ejhf.​111 CrossRefPubMed
35.
go back to reference Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Group ESCSD (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801. https://doi.org/10.1093/eurheartj/ehw211 CrossRefPubMed Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Group ESCSD (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801. https://​doi.​org/​10.​1093/​eurheartj/​ehw211 CrossRefPubMed
36.
go back to reference Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, Investigators C-H (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 36:657–668. https://doi.org/10.1093/eurheartj/ehu385 CrossRefPubMed Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, Investigators C-H (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 36:657–668. https://​doi.​org/​10.​1093/​eurheartj/​ehu385 CrossRefPubMed
39.
go back to reference Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, Investigators F-HT (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448. https://doi.org/10.1056/NEJMoa0908355 CrossRefPubMed Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, Investigators F-HT (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448. https://​doi.​org/​10.​1056/​NEJMoa0908355 CrossRefPubMed
40.
go back to reference Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flogel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T (2017) Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J 38:362–372. https://doi.org/10.1093/eurheartj/ehw333 PubMedCrossRef Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flogel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T (2017) Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J 38:362–372. https://​doi.​org/​10.​1093/​eurheartj/​ehw333 PubMedCrossRef
42.
go back to reference Saitoh M, Dos Santos MR, Ebner N, Emami A, Konishi M, Ishida J, Valentova M, Sandek A, Doehner W, Anker SD, von Haehling S (2016) Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure. Wien Klin Wochenschr 128:497–504. https://doi.org/10.1007/s00508-016-1112-8 CrossRefPubMed Saitoh M, Dos Santos MR, Ebner N, Emami A, Konishi M, Ishida J, Valentova M, Sandek A, Doehner W, Anker SD, von Haehling S (2016) Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure. Wien Klin Wochenschr 128:497–504. https://​doi.​org/​10.​1007/​s00508-016-1112-8 CrossRefPubMed
46.
go back to reference Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G (1998) Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 98:2709–2715CrossRefPubMed Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G (1998) Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 98:2709–2715CrossRefPubMed
47.
go back to reference Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, Schoene N, Schuler G (2000) Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 283:3095–3101CrossRefPubMed Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, Schoene N, Schuler G (2000) Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 283:3095–3101CrossRefPubMed
48.
go back to reference Hambrecht R, Hilbrich L, Erbs S, Gielen S, Fiehn E, Schoene N, Schuler G (2000) Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral l-arginine supplementation. J Am Coll Cardiol 35:706–713CrossRefPubMed Hambrecht R, Hilbrich L, Erbs S, Gielen S, Fiehn E, Schoene N, Schuler G (2000) Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral l-arginine supplementation. J Am Coll Cardiol 35:706–713CrossRefPubMed
49.
50.
go back to reference Gielen S, Sandri M, Kozarez I, Kratzsch J, Teupser D, Thiery J, Erbs S, Mangner N, Lenk K, Hambrecht R, Schuler G, Adams V (2012) Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 125:2716–2727. https://doi.org/10.1161/CIRCULATIONAHA.111.047381 CrossRefPubMed Gielen S, Sandri M, Kozarez I, Kratzsch J, Teupser D, Thiery J, Erbs S, Mangner N, Lenk K, Hambrecht R, Schuler G, Adams V (2012) Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 125:2716–2727. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​111.​047381 CrossRefPubMed
53.
go back to reference Schafer M, Oeing CU, Rohm M, Baysal-Temel E, Lehmann LH, Bauer R, Volz HC, Boutros M, Sohn D, Sticht C, Gretz N, Eichelbaum K, Werner T, Hirt MN, Eschenhagen T, Muller-Decker K, Strobel O, Hackert T, Krijgsveld J, Katus HA, Berriel Diaz M, Backs J, Herzig S (2016) Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia. Mol Metab 5:67–78. https://doi.org/10.1016/j.molmet.2015.11.004 CrossRefPubMed Schafer M, Oeing CU, Rohm M, Baysal-Temel E, Lehmann LH, Bauer R, Volz HC, Boutros M, Sohn D, Sticht C, Gretz N, Eichelbaum K, Werner T, Hirt MN, Eschenhagen T, Muller-Decker K, Strobel O, Hackert T, Krijgsveld J, Katus HA, Berriel Diaz M, Backs J, Herzig S (2016) Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia. Mol Metab 5:67–78. https://​doi.​org/​10.​1016/​j.​molmet.​2015.​11.​004 CrossRefPubMed
54.
go back to reference Valentova M, von Haehling S, Bauditz J, Doehner W, Ebner N, Bekfani T, Elsner S, Sliziuk V, Scherbakov N, Murin J, Anker SD, Sandek A (2016) Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J 37:1684–1691. https://doi.org/10.1093/eurheartj/ehw008 CrossRefPubMed Valentova M, von Haehling S, Bauditz J, Doehner W, Ebner N, Bekfani T, Elsner S, Sliziuk V, Scherbakov N, Murin J, Anker SD, Sandek A (2016) Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J 37:1684–1691. https://​doi.​org/​10.​1093/​eurheartj/​ehw008 CrossRefPubMed
56.
go back to reference Sandek A, Anker SD, von Haehling S (2009) The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab 10:22–28CrossRefPubMed Sandek A, Anker SD, von Haehling S (2009) The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab 10:22–28CrossRefPubMed
63.
go back to reference Boekstegers P, Hausleiter J, Baldus S, von Bardeleben RS, Beucher H, Butter C, Franzen O, Hoffmann R, Ince H, Kuck KH, Rudolph V, Schafer U, Schillinger W, Wunderlich N, Germany Society of Cardiology Working Group on Interventional Cardiology Focus Group on Interventional Mitral Valve T (2014) Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 103:85–96. https://doi.org/10.1007/s00392-013-0614-x CrossRefPubMed Boekstegers P, Hausleiter J, Baldus S, von Bardeleben RS, Beucher H, Butter C, Franzen O, Hoffmann R, Ince H, Kuck KH, Rudolph V, Schafer U, Schillinger W, Wunderlich N, Germany Society of Cardiology Working Group on Interventional Cardiology Focus Group on Interventional Mitral Valve T (2014) Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 103:85–96. https://​doi.​org/​10.​1007/​s00392-013-0614-x CrossRefPubMed
65.
go back to reference Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ (2001) Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103:1759–1764CrossRefPubMed Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ (2001) Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103:1759–1764CrossRefPubMed
67.
go back to reference Franzen O, van der Heyden J, Baldus S, Schluter M, Schillinger W, Butter C, Hoffmann R, Corti R, Pedrazzini G, Swaans MJ, Neuss M, Rudolph V, Surder D, Grunenfelder J, Eulenburg C, Reichenspurner H, Meinertz T, Auricchio A (2011) MitraClip(R) therapy in patients with end-stage systolic heart failure. Eur J Heart Fail 13:569–576. https://doi.org/10.1093/eurjhf/hfr029 CrossRefPubMed Franzen O, van der Heyden J, Baldus S, Schluter M, Schillinger W, Butter C, Hoffmann R, Corti R, Pedrazzini G, Swaans MJ, Neuss M, Rudolph V, Surder D, Grunenfelder J, Eulenburg C, Reichenspurner H, Meinertz T, Auricchio A (2011) MitraClip(R) therapy in patients with end-stage systolic heart failure. Eur J Heart Fail 13:569–576. https://​doi.​org/​10.​1093/​eurjhf/​hfr029 CrossRefPubMed
68.
go back to reference Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, Kuck KH, Konorza T, Mollmann H, Hehrlein C, Ouarrak T, Senges J, Meinertz T, German Transcatheter Mitral Valve Interventions i (2012) MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 14:1050–1055. https://doi.org/10.1093/eurjhf/hfs079 CrossRefPubMed Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, Kuck KH, Konorza T, Mollmann H, Hehrlein C, Ouarrak T, Senges J, Meinertz T, German Transcatheter Mitral Valve Interventions i (2012) MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 14:1050–1055. https://​doi.​org/​10.​1093/​eurjhf/​hfs079 CrossRefPubMed
69.
go back to reference Geis NA, Puls M, Lubos E, Zuern CS, Franke J, Schueler R, von Bardeleben RS, Boekstegers P, Ouarrak T, Zahn R, Ince H, Senges J, Katus HA, Bekeredjian R (2018) Safety and efficacy of MitraClip therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:598–608. https://doi.org/10.1002/ejhf.910 CrossRefPubMed Geis NA, Puls M, Lubos E, Zuern CS, Franke J, Schueler R, von Bardeleben RS, Boekstegers P, Ouarrak T, Zahn R, Ince H, Senges J, Katus HA, Bekeredjian R (2018) Safety and efficacy of MitraClip therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:598–608. https://​doi.​org/​10.​1002/​ejhf.​910 CrossRefPubMed
71.
go back to reference Lutter G, Pokorny S, Frank D, Cremer J, Lozonschi L (2013) Transapical mitral valve implantation: the Lutter valve. Heart Lung Vessel 5:201–206PubMedPubMedCentral Lutter G, Pokorny S, Frank D, Cremer J, Lozonschi L (2013) Transapical mitral valve implantation: the Lutter valve. Heart Lung Vessel 5:201–206PubMedPubMedCentral
74.
go back to reference Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, Investigators M-CT (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–1338. https://doi.org/10.1056/NEJMoa0906431 CrossRefPubMed Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, Investigators M-CT (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–1338. https://​doi.​org/​10.​1056/​NEJMoa0906431 CrossRefPubMed
75.
go back to reference Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, Shinn T, Solomon S, Steinberg JS, Wilber D, Barsheshet A, McNitt S, Zareba W, Klein H, Committee M-CE (2011) Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 124:1527–1536. https://doi.org/10.1161/CIRCULATIONAHA.110.014324 CrossRefPubMed Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, Shinn T, Solomon S, Steinberg JS, Wilber D, Barsheshet A, McNitt S, Zareba W, Klein H, Committee M-CE (2011) Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 124:1527–1536. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​110.​014324 CrossRefPubMed
77.
go back to reference Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuss G (2018) A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. JACC Heart Fail. https://doi.org/10.1016/j.jchf.2018.04.010 CrossRefPubMed Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuss G (2018) A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. JACC Heart Fail. https://​doi.​org/​10.​1016/​j.​jchf.​2018.​04.​010 CrossRefPubMed
80.
go back to reference Ertl G, Angermann CE, Bekeredjian R, Beyersdorf F, Güder G, Gummert J, Katus HA, Kindermann I, Pauschinger M, Perings S, Raake PWJ, Störk S, von Scheidt W, Welz S, Böhm M (2016) 2016 Empfehlung Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF-NETs) und Herzinsuffizienz-Einheiten (“Heart Failure Units”, HFUs) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz. Der Kardiologe 10:222CrossRef Ertl G, Angermann CE, Bekeredjian R, Beyersdorf F, Güder G, Gummert J, Katus HA, Kindermann I, Pauschinger M, Perings S, Raake PWJ, Störk S, von Scheidt W, Welz S, Böhm M (2016) 2016 Empfehlung Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF-NETs) und Herzinsuffizienz-Einheiten (“Heart Failure Units”, HFUs) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz. Der Kardiologe 10:222CrossRef
81.
go back to reference Tschierschke R, Katus HA, Raake PWJ (2013) First “Advanced Heart Failure Unit” at the Heart Centre of the University hospital Heidelberg; example for integrated care structures for optimized treatment of terminal heart failure. Dtsch med Wochenschr 138:603–607CrossRefPubMed Tschierschke R, Katus HA, Raake PWJ (2013) First “Advanced Heart Failure Unit” at the Heart Centre of the University hospital Heidelberg; example for integrated care structures for optimized treatment of terminal heart failure. Dtsch med Wochenschr 138:603–607CrossRefPubMed
82.
go back to reference Frey N, Albrecht A, Bauersachs J, Hasenfuss G, Laufs U, Luchner A, Pauschinger M, Raake P, Sack S, von Scheidt W, Schulze C, Smetak N, Subin B, Herzinsuffizienz DTFC (2018) Curriculum Herzinsuffizienz. Der Kardiologe 12:56–67CrossRef Frey N, Albrecht A, Bauersachs J, Hasenfuss G, Laufs U, Luchner A, Pauschinger M, Raake P, Sack S, von Scheidt W, Schulze C, Smetak N, Subin B, Herzinsuffizienz DTFC (2018) Curriculum Herzinsuffizienz. Der Kardiologe 12:56–67CrossRef
Metadata
Title
Progress in heart failure treatment in Germany
Authors
Mark Luedde
Martina E. Spehlmann
Norbert Frey
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue Special Issue 2/2018
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-018-1317-0

Other articles of this Special Issue 2/2018

Clinical Research in Cardiology 2/2018 Go to the issue